NASDAQ: ATRC
AtriCure, Inc.CIK 0001323885 · SIC 3841 · Surgical & Medical Instruments
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (CRWD 10-Q) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade ATRC commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed Jul 27, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)
(In Thousands, Except Per Share Amounts)
| Description | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Revenue | 153,604 | 136,139 | 294,853 | 259,759 |
| Cost of revenue | 34,975 | 34,657 | 66,913 | 65,649 |
| Gross profit | 118,629 | 101,482 | 227,940 | 194,110 |
| Operating expenses: | ||||
| Research and development expenses | 26,402 | 29,284 | 50,637 | 51,812 |
| Selling, general and administrative expenses | 82,562 | 78,390 | 167,112 | 154,444 |
| Total operating expenses | 108,964 | 107,674 | 217,749 | 206,256 |
| Income (loss) from operations | 9,665 | (6,192) | 10,191 | (12,146) |
| Other income (expense): | ||||
| Interest expense | (1,318) | (1,490) | (2,658) | (2,906) |
| Interest income | 1,179 | 941 | 2,424 | 1,983 |
| Other income (expense) | (100) | 812 | (137) | 632 |
| Income (loss) before income tax expense | 9,426 | (5,929) | 9,820 | (12,437) |
| Income tax expense | 471 | 261 | 757 | 500 |
| Net income (loss) | 8,955 | (6,190) | 9,063 | (12,937) |
| Net income (loss) per share | ||||
| Basic net income (loss) per share | 0.18 | (0.13) | 0.19 | (0.27) |
| Diluted net income (loss) per share | 0.18 | (0.13) | 0.18 | (0.27) |
| Weighted average shares outstanding | ||||
| Basic | 48,667 | 47,721 | 48,501 | 47,557 |
| Diluted | 48,868 | 47,721 | 49,094 | 47,557 |
| Comprehensive income (loss): | ||||
| Foreign currency translation adjustment | (126) | 979 | (465) | 1,784 |
| Net income (loss) | 8,955 | (6,190) | 9,063 | (12,937) |
| Comprehensive income (loss), net of tax | 8,829 | (5,211) | 8,598 | (11,153) |
Condensed Consolidated Balance Sheets (Unaudited)
(In Thousands, Except Per Share Amounts)
| Description | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | 167,786 | 167,428 |
| Accounts receivable, less allowance for credit losses of $1,000 and $750 | 79,981 | 66,653 |
| Inventories | 83,925 | 78,492 |
| Prepaid and other current assets | 13,839 | 9,944 |
| Total current assets | 345,531 | 322,517 |
| Property and equipment, net | 42,422 | 39,123 |
| Operating lease right-of-use assets | 6,069 | 6,868 |
| Intangible assets, net | 43,258 | 48,026 |
| Goodwill | 234,781 | 234,781 |
| Other noncurrent assets | 4,582 | 2,864 |
| Total Assets | 676,643 | 654,179 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | 35,850 | 25,310 |
| Accrued liabilities | 42,893 | 53,089 |
| Other current liabilities | 3,173 | 3,121 |
| Total current liabilities | 81,916 | 81,520 |
| Long-term debt | 61,000 | 61,865 |
| Finance and operating lease liabilities | 10,048 | 11,516 |
| Other noncurrent liabilities | 7,246 | 7,343 |
| Total Liabilities | 160,210 | 162,244 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ Equity: | ||
| Common stock, $0.001 par value, 90,000 shares authorized and 50,863 and 49,792 issued and outstanding | 51 | 50 |
| Additional paid-in capital | 920,421 | 904,522 |
| Accumulated other comprehensive income | 101 | 566 |
| Accumulated deficit | (404,140) | (413,203) |
| Total Stockholders’ Equity | 516,433 | 491,935 |
| Total Liabilities and Stockholders’ Equity | 676,643 | 654,179 |
Condensed Consolidated Statements of Cash Flows (Unaudited)
(In Thousands)
| Description | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net income (loss) | 9,063 | (12,937) |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||
| Share-based compensation expense | 23,586 | 21,001 |
| Depreciation | 5,812 | 6,034 |
| Amortization of intangible assets | 4,768 | 4,221 |
| Amortization of deferred financing costs | 210 | 239 |
| Acquired in-process research and development expense | — | 5,000 |
| Other non-cash adjustments | 1,177 | 311 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (13,780) | (4,844) |
| Inventories | (5,641) | (74) |
| Other current assets | (3,961) | (1,482) |
| Accounts payable | 9,017 | (45) |
| Accrued liabilities | (10,060) | (5,832) |
| Other noncurrent assets and liabilities | (1,995) | (1,001) |
| Net cash provided by operating activities | 18,196 | 10,591 |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (7,618) | (4,843) |
| Acquisitions, including in-process research and development | — | (5,000) |
| Proceeds from capital grant | — | 500 |
| Net cash used in investing activities | (7,618) | (9,343) |
| Cash flows from financing activities: | ||
| Payments on debt, leases and financing obligation | (1,528) | (579) |
| Payment of financing costs and debt fees | (779) | — |
| Shares repurchased for payment of taxes on stock awards | (11,756) | (10,578) |
| Proceeds from stock option exercises and employee stock purchase plan | 4,070 | 4,251 |
| Net cash used in financing activities | (9,993) | (6,906) |
| Effect of exchange rate changes on cash and cash equivalents | (227) | 733 |
| Net increase (decrease) in cash and cash equivalents | 358 | (4,925) |
| Cash and cash equivalents—beginning of period | 167,428 | 122,721 |
| Cash and cash equivalents—end of period | 167,786 | 117,796 |
| Supplemental cash flow information: | ||
| Cash paid for interest | 2,385 | 2,574 |
| Cash paid for taxes, net of refunds | 1,053 | 882 |
| Non-cash investing and financing activities: | ||
| Accrued purchases of property and equipment | 2,989 | 895 |
Amounts as printed on the EDGAR/iXBRL face — (In Thousands, Except Per Share Amounts); (In Thousands). Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗